MF
UTHR icon

Meridian Financial’s United Therapeutics UTHR Stock Holding History

Meridian Financial’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-400
Closed -$237K – 150
2026
Q1 		$237K Sell
400
-290
-42% -$144K 0.13% 131
2025
Q4 		$336K Sell
690
-90
-12% -$41.9K 0.18% 100
2025
Q3 		$327K Hold
780
– – 0.18% 95
2025
Q2 		$224K Hold
780
– – 0.15% 115
2025
Q1 		$240K Hold
780
– – 0.17% 99
2024
Q4 		$275K Hold
780
– – 0.19% 92
2024
Q3 		$280K Hold
780
– – 0.19% 102
2024
Q2 		$248K Sell
780
-220
-22% -$58.2K 0.18% 104
2024
Q1 		$230K Hold
1,000
– – 0.17% 110
2023
Q4 		$220K Hold
1,000
– – 0.17% 102
2023
Q3 		$226K Sell
1,000
-120
-11% -$27.6K 0.21% 91
2023
Q2 		$247K Hold
1,120
– – 0.22% 83
2023
Q1 		$251K Buy
+1,120
New +$276K 0.24% 80

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Meridian Financial's UTHR Position: Q2 2026 in Review

Meridian Financial sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 400 shares — an estimated $237K sold.

Meridian Financial first reported a position in UTHR in Q1 2023 and held it in 13 quarters. The position peaked at $336K in Q4 2025. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Meridian Financial reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Meridian Financial sold 400 United Therapeutics shares in Q2 2026, an estimated $237K.
  • Meridian Financial first reported a position in United Therapeutics in Q1 2023 and held it in 13 quarters.
  • Meridian Financial's United Therapeutics position peaked at $336K in Q4 2025.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Meridian Financial's 13F filing for Q2 2026, filed 22 Jul 2026.